Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
44 hedge funds and large institutions have $7.51M invested in Clearside Biomedical in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 43 → 44 (+1)
0.04% more ownership
Funds ownership: 0.76% → 0.81% (+0.04%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
7% less capital invested
Capital invested by funds: $8.09M → $7.51M (-$581K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$460K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$275K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.7K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$13.2K |
| 5 |
GWP
Gen-Wealth Partners
Zeeland,
Michigan
|
+$8.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$145K |
| 2 |
Renaissance Technologies
New York
|
-$47.9K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$41.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$24.4K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$22.4K |
CLSD Hedge Fund Activity: Q2 2025 in Review
44 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2025, worth a combined $7.51M — down 7.2% from $8.09M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CLSD positions and 5 closed out — a net gain of 1 holder — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $460K. The largest seller was BlackRock, cutting an estimated $145K.
- 44 institutional investors held Clearside Biomedical (CLSD) as of Q2 2025, up from 43 in Q1 2025.
- Funds reported $7.51M of Clearside Biomedical stock for Q2 2025, down 7.2% quarter-over-quarter.
- 6 funds opened new Clearside Biomedical positions in Q2 2025 and 5 closed out, a net change of +1 holder.
- The largest Clearside Biomedical buyer in Q2 2025 was Vanguard Group, an estimated $460K added.
- The largest Clearside Biomedical seller in Q2 2025 was BlackRock, an estimated $145K sold.
Based on aggregated 13F filings for Q2 2025.